Clinical Policy: Methoxy Polyethylene Glycol-Epoetin Beta (Mircera)
Defines medical necessity criteria, prior authorization expectations, dosing, exclusions, and coding implications for Mircera (methoxy polyethylene glycol-epoetin beta) for treatment of anemia of chronic kidney disease across commercial, HIM and Medicaid lines of business, including pediatric use and step therapy redirection to alternative ESAs.
Expanded pediatric use down to 3 months of age for patients on dialysis and added use in pediatric patients not on dialysis per updated prescribing information; added SC route option in pediatrics.
Added requirement for continuation requests that current hemoglobin < 12 g/dL and updated adult dosing to include 1.2 mcg/kg once monthly for CKD not on dialysis.
Extended continuation therapy approval duration from 6 to 12 months for Medicaid/HIM.
Revised Retacrit and Epogen redirection language from 'failure of' to 'member must use' and clarified members must use Epogen if unable to use Retacrit; added step therapy bypass for IL HIM per IL HB 5395.
Added Appendix D referencing KDIGO guidelines that do not indicate preference for any ESA.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.